Hepatokines and adipokines in NASH-related hepatocellular carcinoma

Autores
Kucukoglu, Ozlem; Sowa, Jan Peter; Mazzolini Rizzo, Guillermo Daniel; Syn, Wing Kin; Canbay, Ali
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, preventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipokines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions underlying alterations to hepatokines and adipokines, current data support the possible utility of these factors – in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin – for detection or even as therapeutic targets in NAFLD-related HCC.
Fil: Kucukoglu, Ozlem. Otto-von-Guericke-Universität Magdeburg; Alemania
Fil: Sowa, Jan Peter. Ruhr Universität Bochum; Alemania
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Syn, Wing Kin. Universidad del País Vasco; España
Fil: Canbay, Ali. Otto-von-Guericke-Universität Magdeburg; Alemania
Materia
ADIPOKINES
CIRRHOSIS
HEPATOKINES
LIVER
NAFLD
NASH
OBESITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/163895
Acceder
id CONICETDig_ded5070bae0ba116a81d423e051afaf8
oai_identifier_str oai:ri.conicet.gov.ar:11336/163895
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Hepatokines and adipokines in NASH-related hepatocellular carcinomaKucukoglu, OzlemSowa, Jan PeterMazzolini Rizzo, Guillermo DanielSyn, Wing KinCanbay, AliADIPOKINESCIRRHOSISHEPATOKINESLIVERNAFLDNASHOBESITYhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, preventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipokines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions underlying alterations to hepatokines and adipokines, current data support the possible utility of these factors – in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin – for detection or even as therapeutic targets in NAFLD-related HCC.Fil: Kucukoglu, Ozlem. Otto-von-Guericke-Universität Magdeburg; AlemaniaFil: Sowa, Jan Peter. Ruhr Universität Bochum; AlemaniaFil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; ArgentinaFil: Syn, Wing Kin. Universidad del País Vasco; EspañaFil: Canbay, Ali. Otto-von-Guericke-Universität Magdeburg; AlemaniaElsevier Science2021-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/163895Kucukoglu, Ozlem; Sowa, Jan Peter; Mazzolini Rizzo, Guillermo Daniel; Syn, Wing Kin; Canbay, Ali; Hepatokines and adipokines in NASH-related hepatocellular carcinoma; Elsevier Science; Journal of Hepatology; 74; 2; 2-2021; 442-4570168-8278CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhep.2020.10.030info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:58:26Zoai:ri.conicet.gov.ar:11336/163895instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:58:26.399CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hepatokines and adipokines in NASH-related hepatocellular carcinoma
title Hepatokines and adipokines in NASH-related hepatocellular carcinoma
spellingShingle Hepatokines and adipokines in NASH-related hepatocellular carcinoma
Kucukoglu, Ozlem
ADIPOKINES
CIRRHOSIS
HEPATOKINES
LIVER
NAFLD
NASH
OBESITY
title_short Hepatokines and adipokines in NASH-related hepatocellular carcinoma
title_full Hepatokines and adipokines in NASH-related hepatocellular carcinoma
title_fullStr Hepatokines and adipokines in NASH-related hepatocellular carcinoma
title_full_unstemmed Hepatokines and adipokines in NASH-related hepatocellular carcinoma
title_sort Hepatokines and adipokines in NASH-related hepatocellular carcinoma
dc.creator.none.fl_str_mv Kucukoglu, Ozlem
Sowa, Jan Peter
Mazzolini Rizzo, Guillermo Daniel
Syn, Wing Kin
Canbay, Ali
author Kucukoglu, Ozlem
author_facet Kucukoglu, Ozlem
Sowa, Jan Peter
Mazzolini Rizzo, Guillermo Daniel
Syn, Wing Kin
Canbay, Ali
author_role author
author2 Sowa, Jan Peter
Mazzolini Rizzo, Guillermo Daniel
Syn, Wing Kin
Canbay, Ali
author2_role author
author
author
author
dc.subject.none.fl_str_mv ADIPOKINES
CIRRHOSIS
HEPATOKINES
LIVER
NAFLD
NASH
OBESITY
topic ADIPOKINES
CIRRHOSIS
HEPATOKINES
LIVER
NAFLD
NASH
OBESITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, preventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipokines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions underlying alterations to hepatokines and adipokines, current data support the possible utility of these factors – in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin – for detection or even as therapeutic targets in NAFLD-related HCC.
Fil: Kucukoglu, Ozlem. Otto-von-Guericke-Universität Magdeburg; Alemania
Fil: Sowa, Jan Peter. Ruhr Universität Bochum; Alemania
Fil: Mazzolini Rizzo, Guillermo Daniel. Universidad Austral. Facultad de Ciencias Biomédicas. Instituto de Investigaciones en Medicina Traslacional. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones en Medicina Traslacional; Argentina
Fil: Syn, Wing Kin. Universidad del País Vasco; España
Fil: Canbay, Ali. Otto-von-Guericke-Universität Magdeburg; Alemania
description The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form non-alcoholic steatohepatitis (NASH), and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, prognosis and survival do not differ between NAFLD- or virus-associated HCC. Thus, research has increasingly focused on NAFLD-related risk factors to better understand the biology of hepatocarcinogenesis and to develop new diagnostic, preventive, and therapeutic strategies. One important aspect thereof is the role of hepatokines and adipokines in NAFLD/NASH-related HCC. In this review, we compile current data supporting the use of hepatokines and adipokines as potential markers of disease progression in NAFLD or as early markers of NAFLD-related HCC. While much work must be done to elucidate the mechanisms and interactions underlying alterations to hepatokines and adipokines, current data support the possible utility of these factors – in particular, angiopoietin-like proteins, fibroblast growth factors, and apelin – for detection or even as therapeutic targets in NAFLD-related HCC.
publishDate 2021
dc.date.none.fl_str_mv 2021-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/163895
Kucukoglu, Ozlem; Sowa, Jan Peter; Mazzolini Rizzo, Guillermo Daniel; Syn, Wing Kin; Canbay, Ali; Hepatokines and adipokines in NASH-related hepatocellular carcinoma; Elsevier Science; Journal of Hepatology; 74; 2; 2-2021; 442-457
0168-8278
CONICET Digital
CONICET
url http://hdl.handle.net/11336/163895
identifier_str_mv Kucukoglu, Ozlem; Sowa, Jan Peter; Mazzolini Rizzo, Guillermo Daniel; Syn, Wing Kin; Canbay, Ali; Hepatokines and adipokines in NASH-related hepatocellular carcinoma; Elsevier Science; Journal of Hepatology; 74; 2; 2-2021; 442-457
0168-8278
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jhep.2020.10.030
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science
publisher.none.fl_str_mv Elsevier Science
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613741192151040
score 13.070432

Publicaciones similares